heart disease

Regenxbio Inc. (NASDAQ:RGNX) shares are down on Wednesday after the company reported new interim data from its Phase 1/2 AFFINITY DUCHENNE trial of RGX-202. • Regenxbio stock is among today’s weakest performers. Why is RGNX stock dropping? Improved Motor Functions In Duchenne Patients...

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) stock is trading lower on Friday, with a session volume of 42.39 million compared to the average volume of 3.51 million as per data from Benzinga Pro. • Tenaya Therapeutics stock is feeling bearish pressure. What’s pressuring TNYA stock? On...

Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity medication, Wegovy, has been shown to cause more weight loss in women with prevalent heart disease than in men with the same condition. What Happened: In a recent analysis of study data, involving 1,145 patients, centered on a condition known as...

Today, Cytokinetics Incorporated (NASDAQ: CYTK) reported positive REDWOOD-HCM Phase 2 data showing CK-274 treatment for ten weeks resulted in substantial and statistically significant reductions in the average resting left ventricular outflow tract pressure gradient (LVOT-G) and...

Cytokinetics Incorporated (NASDAQ: CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274) in hypertrophic cardiomyopathy (HCM).  The Company plans to initiate Phase 3 trial by the end of 2021. Results demonstrated...

The plot deepens regarding the biotech company Amarin (NASDAQ: AMRN) and its controversial cholesterol-controlling drug, Vascepa. As previously reported on Benzinga, Amarin was waiting to hear the results of a Food and Drug Administration ruling. The company had appealed the FDA's October...